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Portal hypertension is one of the major complications
of chronic liver disease and cirrhosis. The presence of
portal hypertension is related to the formation of
esophageal varices, ascites and fluid and electrolyte
redistribution, hepatorenal syndrome, and hepatic
encephalopathy [1–3].
Development of imaging system has improved
clinical diagnosis of cirrhosis. The images help iden-
tify structural changes of the liver, portal hyperten-
sion and collaterals, ascites, and vascular change.
Clinical evaluation of portal hypertension may 
predict the development of esophageal and gas-
tric varices, prevent variceal hemorrhage, predict
survival rate, and assess the efficacy of treatment of
portal hypertension [4]. Sonography has been widely
used for the follow-up of chronic liver diseases in
identifying cirrhosis and hepatocellular carcinoma.
The sonographic findings of increasing diameter and
irregular shape of portal vein (PV), increasing col-
laterals and the presence of ascites and splenomeg-
aly may suggest portal hypertension and cirrhosis.
The hemodynamic change of the portal system has
been assessed by using duplex Doppler ultrasound,
hepatic vein (HV) catheterization [5], computed
tomography [6], magnetic resonance imaging [7],
and portal scintigraphy [8].
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namics of the portal system. Doppler sonography can identify and localize the course and
dynamic of blood flow. Ultrasound contrast agents are gas-filled microbubbles that can
improve the flow with poor Doppler signal quality. The main portal vein flow velocity and
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Noninvasive duplex Doppler ultrasound can 
be utilized repeatedly in assessing the hemody-
namics of the portal system [9]. The velocity and
direction of blood flow are assessed by measuring
the Doppler shift. The direction of blood flow is
shown in red and blue color, and the color intensity
represents the flow velocity. Color Doppler sono-
graphy can identify and localize the course and
dynamic of blood flow. In power Doppler sono-
graphy, the Doppler signal amplitude is squared 
to show the small blood vessels with low blood flow
velocities. Tissue harmonic imaging can enhance the
spatial and contrast resolution of B-mode images.
Ultrasound contrast agents are gas-filled micro-
bubbles with diameters in the micrometer range
to improve the flow with poor Doppler signal
quality [10–12].
Portal hypertension occurs in various etiologies.
The color Doppler sonography is useful in the
identification and localization of collaterals devel-
oped in portal hypertension, including umbilical
vein, coronary gastric veins, esophageal collaterals,
and collaterals in splenic hilum [13]. Invasive modal-
ities for studying portal circulation are often not
appropriate in patients having severe acute hepati-
tis or cirrhosis with hepatic failure, poor blood
coagulation and ascites. Ultrasonic Doppler is safe
and noninvasive in clinical evaluation of the portal
blood flow, even in the case of patients with liver
failure.
Doppler sonography is helpful in the follow-up
of surgical intervention such as portacaval shunt,
splenorenal shunt, transjugular intrahepatic shunt,
hepatectomy, and liver transplantation [14–20]. PV
thrombosis is shown by tumor thrombus and
undetectable flow inside the PV [21,22]. Contrast-
enhanced sonography is superior to Doppler sonog-
raphy for the detection of portal and HV thrombosis
complicating malignancies [23,24]. Doppler sono-
graphy can assess intrahepatic hemodynamics and
shunt patency before and after transjugular intra-
hepatic portosystemic shunt [25–28]. Findings of
increased hepatic artery (HA) blood flow velocity
and decreased portal blood flow velocity suggest
liver regeneration after liver transplantation [29].
Doppler sonography may detect HA stenosis or
thrombosis in patients who have undergone liver
transplantation [30,31]. Hepatic arterial stenosis or
thrombosis is observed as a change in the spectral
waveform to a tardus-parvus pattern [32].
Variability
The measurement of portal blood flow often has
high variability. The interobserver and intraobserver
variability should be measured to ensure the data
reliability [33,34]. Portal blood flow is better meas-
ured by the same technician or physician to avoid
interobserver variation. The portal blood flow from
the controls are measured twice at 30 minutes apart
in the same day (A vs. B) and at the same time on
consecutive days (A vs. C). The percent difference
of intraobserver variability is calculated by the equa-
tion: absolute values of (A − B)/A × 100 or (A − C)/
A × 100. Coefficient of variation is calculated by the
equation: (standard deviation/mean) × 100. Ultra-
sonic contrast agent has been reported to be 
able to reduce interobserver and inter-equipment
variability [35].
Portal Vein Pulsatility 
Index (PVPI)
PVPI is calculated by the equation: (maximum −
minimum)/maximum frequency shift [36]. PVPI is
significantly lower in patients with chronic liver
disease and cirrhosis [37]. Color duplex sonogra-
phy can be used to differentiate the hepatofugal,
stagnant and hepatopetal direction of flow. Stagnant
portal flow is presented as no detectable flow,
which may occur during a right heart failure [36].
Hepatofugal portal flow can be identified by obser-
vation of reversed portal vein flow (PVF) in cirrhotics
[38]. The markedly increased PVPI can predict a
right heart failure [36,39]. Transient stagnant and
hepatofugal portal flow may occur in the case of
severe right heart failure, mainly during the 
ventricular systole [36].
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PVF
The main PVF velocity and volume can be mea-
sured using duplex sonography. Mean portal blood
velocity is calculated using the equation: mean
portal blood velocity (cm/s) = 0.57 × mean maxi-
mum portal blood velocity (cm/s) [40]. The cross-
sectional area can be recorded at the main PV site
where the portal blood velocity is measured. Esti-
mated PVF is calculated using the equation: por-
tal blood flow volume (mL/min) = cross-sectional
area (cm2) × mean portal blood velocity (cm/s) × 60
seconds [40].
The PVF is reduced by 80% after 60 minutes of
exercise [41]. In healthy pregnant women, the por-
tal venous blood flow significantly increases after
28 weeks of gestation and the hepatic arterial blood
flow remains unchanged [42].
In severe acute hepatitis, PVF decreases in patients
having ascites [43]. Patients with severe acute hepati-
tis may have decreased PVF because of the increased
sinusoidal pressure without well-developed portosys-
temic collaterals. Higher serum-ascites albumin gra-
dient positively correlates with higher PVF in severe
acute hepatitis patients with ascites [44]. Lower PVF
is also identified in patients with fulminant hepatic
failure [45] and hepatic encephalopathy [46,47].
In chronic liver diseases, portosystemic collater-
als contribute as an important factor in the hyper-
dynamic state [48]. Patients with chronic hepatitis
and cirrhosis have reduced portal blood flow veloc-
ity [49,50]. Patients with chronic hepatitis C that
have responded to interferon therapy have signifi-
cant increases in portal blood flow velocity at the
end of interferon treatment [51]. In patients with
alcoholic cirrhosis, PV blood velocity and flow are
correlated to the severity of portal hypertension
and to the severity of liver failure [52].
Cirrhotics with the lowest portal velocity have
esophageal and gastric varices with a red color
sign [49]. The presence of a non-hepatopetal flow
pattern implicates an increased risk of esophageal
varices bleeding [53]. Decreased right portal venous
peak velocity is a risk factor for postoperative
hyperbilirubinemia [54].
Doppler sonography is also helpful in the 
follow-up of the changes of portal hemodynamics
under medical treatment such as somatostatin, ter-
lipressin, nitroglycerin, vardenafil, propranolol and
nadolol [55–60]. Large-volume paracentesis does not
change the portal hemodynamics 24 hours after
paracentesis [61].
Portal Vein Congestion Index (PVCI)
PVCI has been used to assess the pathophysiologic
hemodynamics of portal venous system in differ-
ent forms of liver diseases [62–64]. PVCI is calcu-
lated by the equation: (area/mean portal blood
velocity) × 100 [62]. PVCI has a significant increase
in patients with Child’s C cirrhosis [65]. Patients
with esophageal variceal bleeding have significantly
greater splenic blood flow volume and splenic vein
congestion index [66]. A study confirms that portal
hypertension is associated with patients with high
PVCI [67]. Patients with variceal red signs have sig-
nificantly higher PVF and PVCI than patients without
the red signs, and their perfusion pressure gradients
are lower [68]. However, subsequent studies show
that portal hemodynamics is unrelated to the degree
of endoscopic abnormalities in patients with liver
cirrhosis [69].
Parasympathetic hypofunction, sympathetic hy-
perfunction and portal hemodynamics are closely
related to gastric motility in cirrhotic patients [70].
The postprandial PVF increments are low in patients
with esophageal varices of any degree and class B
and C cirrhosis. There is no postprandial decrease
in PVCI in patients with severe cirrhosis [71].
Hepatic Artery Resistance Index (HARI)
HARI is calculated by the equation: (peak systolic
value − end diastolic value)/peak systolic value [72].
In PV thrombosis, reduced HARI is helpful for deter-
mining venous abnormality [72]. HARI is significantly
higher in patients with cirrhosis and is directly corre-
lated with the hepatic venous pressure gradient [73].
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Ethanol-related hepatic arterial vasodilation occurs
in alcoholic hepatitis and alcoholic patients without
liver damage; HA resistance significantly increases
in alcoholic and viral-related cirrhosis [74,75]. HARI
may detect an increase in vascular resistance in acute
liver transplant rejection [76]. Pre-transplant HARI
is not correlated with clinical outcome and hospital
stay [77]. Patients with fatty liver have higher HARI
due to an increase in intrahepatic resistance, which
can be reversed by metformin treatment [78,79].
Hepatic Circulatory Index (HCI)
HCI (cm2/s2) is calculated by using the formula: right
portal venous peak velocity (cm/s) × right hepatic
arterial peak systolic velocity (cm/s)/splenic arterial
pulsatility index (SAPI); patients with hepatitis or
cirrhosis have lower HCI [80].
SAPI
High SAPI predicts prolonged postoperative ascites
[54]. An increase in SAPI can predict acute rejec-
tion after a liver transplantation [75]. A decrease in
SAPI also occurs in small-for-gestational-age fetuses
[81,82]. The pulsatility index in the splanchnic area,
including SAPI, rises steeply in old patients, proba-
bly as a result to compensate decreased cardiac
output [83]. Intrarenal arterial pulsatility index and
resistive index are higher in cases of portal hyper-
tension with ascites [84,85]. Renal vasoconstriction
causes an increase in renal vascular resistance, which
can be detected by Doppler ultrasonography [86].
Hepatic Perfusion Index (HPI)
HPI is measured by the ratio of hepatic arterial to
total liver blood flow (sum of hepatic arterial and
portal venous blood flow); a value between 0.3
and 0.8 (normal < 0.26) is sensitive enough to
detect occult colorectal liver metastases [87,88]. HPI
is higher in colorectal liver metastases with reduction
of portal inflow and subsequently increased hepa-
tic arterial blood flow [89,90]. Other studies have
not confirmed the role of HPI in predicting occult
hepatic colorectal metastases [91]. Obese patients
have significantly higher HPI values [92]. Fatty liver
index is measured by the equation: 1.03 × aspar-
tate aminotransferase (IU/L) + 0.152 × triglyceride
(mg/dL) −49.75 × HPI [92].
Intrahepatic Circulatory Time
Intrahepatic circulatory time is calculated as the
difference between the HV and HA arrival times
(HV − HA interval time) or the HV and PV arrival
times (HV − PV interval time). Intrahepatic circula-
tory time has been used as a diagnostic test for
compensated cirrhosis [93].
Hepatic Vein Waveforms (HVWs)
Poorer grade of cirrhosis has higher mean HV veloc-
ity; cirrhotics with high HV velocity of ≥ 20 cm/s 
is presented clinically with moderate to massive
ascites [94]. HVW is useful in the noninvasive eval-
uation of severity of portal hypertension; biphasic
and monophasic HVW are associated with severe
portal hypertension [95–97]. Non-triphasic HVW
may assess the progression of chronic viral hepatitis
and grading of cirrhosis [98]. Monophasic or bipha-
sic HVW occurs in children with acute viral hepatitis,
especially when accompanied by change in hepatic
echogenicity [99].
Patients with fatty liver may also develop abnor-
mal biphasic or monophasic HVW patterns [100].
Abnormal hepatic venous flow velocities are signs of
abnormal right ventricular filling pattern before a
cardiac surgery, which are associated with increasing
need for vasoactive support after a cardiopulmonary
bypass [101]. However, recent studies suggest that
monophasic HVW may occur in apparently healthy
patients [102]. HVW pattern has a limited clinical
role in the assessment of hepatic fibrosis or inflam-
mation in patients with chronic hepatitis C [103].
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Hepatic Vein Transit Time (HVTT)
Hepatic cirrhosis is accompanied by arterialization
of the liver, intrahepatic shunts, pulmonary arterio-
venous shunts and hyperdynamic circulatory state.
The hepatic first pass of a bolus of an ultrasound
contrast agent injected into a peripheral vein is
accelerated in patients with cirrhosis [104]. HVTT
is measured as the time after Levovist injection at
which a sustained signal increase of > 10% of base-
line was seen. An early arrival time of a microbub-
ble in a HV of less than 24 seconds is a sensitive
indicator of cirrhosis [105,106].
Recent progress of sonography improves imaging
diagnosis. Color flow images of esophageal varices
and para-esophageal veins can be generated by
the newly developed electronic radial endoscopic
Doppler ultrasonography and contrast agents; pul-
satile waves in esophageal varices could also be
detected, suggesting that arterial flow is involved 
in the formation of esophageal varices [107,108].
When a liver is scanned in the pulse-inversion mode
for at least 2 minutes after a Levovist injection,
increased intensity is shown in liver parenchyma;
microbubbles of Levovist accumulating in liver paren-
chyma have been reported occurring in late liver-
specific parenchymal phase [109]. Pulse-inversion
ultrasonography is used to detect the liver paren-
chymal phase of Levovist. The increased vascular
resistance in cirrhosis reduces portal perfusion and
Levovist accumulation. Microbubble disruption of
the liver parenchyma in the late phase of enhance-
ment with Levovist is considered to be lower in cases
with cirrhosis [109]. Scanning in pulse-inversion
mode after a Levovist injection improves the detec-
tion of liver metastasis and reveals much smaller
size lesions than conventional ultrasonography and
computed tomography [110].
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